#1
|
|||
|
|||
È âñå òàêè åù¸ ðàç î íîîòðîïàõ
Âñåì èçâåñòíî, ÷òî â ÑØÀ êðèòè÷åñêîå îòíîøåíèå ê íîîòðîïàì â ïðèíöèïå. Íî íåäàâíî îáùàëñÿ ñ êîëëåãîé îòòóäà è îí ðàññêàçàë ìíå, ÷òî ó íèõ äîñòàòî÷íî ïîïóëÿðíû ïðåïàðàòû íà îñíîâå ýêñòðàêòà Ginkgo Biloba EGb 761 (Ìåìîïëàíò, Òàíàêàí, Ãèíêîð. Ýêñòðàêò áûë èçîáðåòåí è ñòàíäàðòèçèðîâàí ïî ðÿäó âåùåñòâ â Ãåðìàíèè. Ñåé÷àñ î÷åíü ìíîãî ïðîèçâîäèòåëåé ýòîãî ëåê. ñðåäñòâà). Íî áîëüøå âñåãî ìåíÿ óäèâèëî, ÷òî ñàìè âðà÷è ÷àñòî ïðèíèìàþò ýòè ïðåïàðàòû äëÿ "óñòîé÷èâîñòè ê ñòðåññó". Ó ìåíÿ åñòü íåáîëüøîé îïûò ïðèìåíåíèÿ ýòîãî ïðåïàðàòà. Êëèíè÷åñêè íàáëþäàåòñÿ äîñòàòî÷íî íåïëîõîé ýôôåêò ó "ðåàáèëèòàöèîííûõ" ïàöèåíòîâ ïîñëå ÒÈÀ, èíñóëüòîâ, ó ïàöèåíòîâ ñ äåìåíöèåé.
Õîòåëîñü áû óçíàòü ìíåíèå êîëëåã. |
#2
|
||||
|
||||
ïðåïàðàò óâåëè÷èâàåò ðèñê êðîâîòå÷åíèé, îñîáåííî ó ïàöèåíòîâ ïðèíèìàþøèõ îäíîâðåìåííî êóìàäèí èëè àñïèðèí.
Ginkgo Biloba The active ingredients in Ginkgo biloba extract account for its antioxidant properties and its ability to inhibit platelet aggregation. Consequently, this herbal product is promoted for use in improving cognitive function and blood flow. To date, however, at least four reports of spontaneous bleeding in association with use of Ginkgo biloba. May increase the possibility of bleeding if taken with Aspirin, warfarin (Coumadin), ticlopidine (Ticlid), clopidogrel (Plavix), dipyridamole (Persantine) |
#3
|
||||
|
||||
Ê ñîæàëåíèþ, êëèíè÷åñêîå âïå÷àòëåíèå îá ýôôåêòèâíîñòè òîãî èëè èíîãî ïðåïàðàòà âåñüìà ñóáúåêòèâíî. Îñîáåííî ýòî êàñàåòñÿ «ðåàáèëèòàöèîííûõ» ïàöèåíòîâ. ß ïðèìåíÿþ ïðåïàðàòû èç ãèíêãî áèëîáû. Íî èëëþçèé ïî ïîâîäó ýòèõ ïðåïàðàòîâ ó ìåíÿ íåò. Äîêàçàòåëüíàÿ áàçà ñëàáàÿ, íî âñå-òàêè ïðèñóòñòâóåò. Ðåçþìå â ýòîì
ïîñòå èç ñòàòüè - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]. Íå äóìàþ, ÷òî àìåðèêàíöû èëè åâðîïåéöû íå ëþáÿò íîîòðîïû. Ïðîñòî íåò îñíîâàíèé äëÿ øèðîêîãî èõ ïðèìåíåíèÿ. Äîêàçàíà íåýôôåêòèâíîñòü ïèðàöåòàìà â ëå÷åíèè èíñóëüòà (èññëåäîâàíèå PASS). Íî îòå÷åñòâåííûå íåâðîëîãè ñ çàâèäíûì óïîðñòâîì ïðîäîëæàþò íàçíà÷àòü ïèðàöåòàì âñåì ïàöèåíòàì, ïåðåíåñøèì èíñóëüò. Âèäèìî íàáëþäàþò êëèíè÷åñêèé ýôôåêò. Âñå äåëî â òîì, ÷òî ïîñëå èíñóëüòà âîññòàíîâëåíèå ìîæåò ïðîèñõîäèòü íåçàâèñèìî îò ëå÷åíèÿ. Êàê îòëè÷èòü óëó÷øåíèå îò ïðåïàðàòà, îò óëó÷øåíèÿ êîòîðîå ïðîèñõîäèò â ñèëó ñàìîñòîÿòåëüíîãî ðåãðåññà ñèìïòîìîâ. Äëÿ ýòîãî íóæíû èññëåäîâàíèÿ. Êîêðàíîâñèé îáçîð: Ginkgo Biloba for Acute Ischemic Stroke Stroke 2006;37;574-575; originally published online Jan 5, 2006; Xianrong Zeng, Ming Liu, Yousong Yang, Yang Li and Kjell Asplund Implications for Practice There is no scientific support from high-quality studies for the routine use of Ginkgo biloba extract in the treatment of patients with acute ischemic stroke. Implications for Research Our meta-analysis suggests that Ginkgo biloba extract intravenous injections and tablets improve neurological impairment after acute ischemic stroke. However, a caveat is that with 1 exception, the trials included were assessed to be of inferior methodological quality. High-quality, large-scale randomized trials are needed to confirm or refute the results. Future trials should overcome the methodological limitations of the trials presented in this review. In particular, they should assure true randomization, adequate concealment of allocation, blinding of outcome assessors, use functional outcome as the primary outcome measured at long-term follow-up, and they should be large enough to provide adequate statistical power. |
#4
|
|||
|
|||
ß òîæå èçðåäêà ïðèìåíÿþ ïðåïàðàòû ãèíêî-áèëîáà ïðè íà÷àëüíûõ êîãíèòèâíûõ íàðóøåíèÿõ. ×åñòíî ñêàçàòü íà ìîé âçãëÿä ýôôåêòèâíîñòü ñîìíèòåëüíà.
|
#5
|
||||
|
||||
Íó óæ åñëè íà òî ïîøëî, åñòü åùå è âàçîáðàë, ñîäåðæàùèé äèãèäðîýðãîêðèïòèí. Ïî íåìó òîæå êîå-êàêàÿ áàçà åñòü, õîòÿ è ñîìíèòåëüíàÿ...
|
#6
|
|||
|
|||
Öèòàòà:
Õîòÿ ñàìî ïîíÿòèå íîîòðîïîâ äîâîëüíî ðàñïëûâ÷àòî. |
#7
|
||||
|
||||
Íå çàìåòèë ïîïóëÿðíîñòè Ãèíêî Áèëîáà ïðè îáùåíèè ñ çàîêåàíñêèìè êîëëåãàìè.
Ïðàâäà ó íèõ íåêîòîðûå ëþäò óïîòðåáëÿþò Ãèíêî êàê ïðîñòî äîáàâêà ê ÷àþ (òèïà ðîìàøêè ó íàñ). Íà ñêîëüêî ÿ çíàþ, â èíñóëüòíîé êëèíèêå íèêàêèõ íåéðîïðîòåêòîðîâ è íîîòðîïîâ íå èñïîëüçóþò (òå êîãî ÿ çíàþ). À àëêîëîèäû ñïîðûíüè ñêîðåå äåéñòâóþò íà àäðåíåðãè÷åñêóþ ñèñòåìó ñîñóäîâ, ÷åì íà íåéðîíû (÷òîá áûòü íåéðîïðîòåêòîðàìè) |
|
#8
|
|||
|
|||
Öèòàòà:
(Koch: Phytomedicine 2005; Markowitz: J Clin Psychopharmacol 2003; Greenblatt: J Clin Pharmacol 2006; Mohutsky: Am J Ther 2006; Engelsen: Thromb Haemost 2002; Bal dit Sollier: Clin Lab Haem 2003; Köhler: Blood Coagul Fibrinolysis 2004; Jiang: Br J Clin Pharmacol 2005; Halil: Blood Coagul Fibrinolysis 2005 Ernst: Perfusion 2005; Gaus: Methods Inf Med 2005; 44: 697-703) |
#9
|
|||
|
|||
Öèòàòà:
Öèòàòà:
|
#10
|
||||
|
||||
Öèòàòà:
Öèòàòà:
|
#11
|
||||
|
||||
Êàê çàîêåàíñêèé êîëëåãà ìîãó ñêàçàòü, ÷òî Ãèíêî ïîïóëÿðåí ñðåäè ðóññêèõ áàáóøåê. Íî îíè ýòî ñåáå ñàìè íàçíà÷àþò.
|
#12
|
|||
|
|||
Öèòàòà:
Íèêòî íå ñïîðèò, ÷òî îíè íåîáõîäèìû. È âåñü ìèð áúåòñÿ íàä èõ ïîèñêîì. Íî ýòî æå íå ïîâîä èñïîëüçîâàòü "íåéðîïðîòåêòîðû", êîòîðûå íè÷åãî íå çàùèùàþò. (ÿ èìåþ ââèäó øèðîêóþ ïðàêòèêó îòå÷åñòâåííîé íåâðîëîãèè) |
#13
|
|||
|
|||
Öèòàòà:
|
#14
|
|||
|
|||
Öèòàòà:
|
#15
|
||||
|
||||
Íà Áðàéòîí Áè÷ åñòü íåêàÿ êîíòîðà "Forces of Nature". Ïðîäàåò è àêòèâíî ðåêëàìèðóåò ÁÀÄ. Åñëè ïîñëóøàòü ðóññêîå ðàäèî, òî ñòàíîâèòñÿ ÿñíî, ÷òî òîëüêî â ýòîé êîíòîðå ìîæíî íàéòè ñàìûå ýôôåêòèâíûå, óíèêàëüíûå, íå èìåþøèå àíàëîãîâ ñðåäñòâà îò âñåõ áîëåçíåé. È âñå áåç ðåöåïòà. è ê âðà÷ó õîäèòü íå íàäî. "Íàøè âûñîêîïðîôåññèîíàëüíûå ñîòðóäíèêè ïîìîãóò âàì ïîäîáðàòü èíäèâèäóàëüíûé êîìïëåêñ". Âîò è Ãèíêî òàì òîæå ðåêëàìèðóåòñÿ. Áàáóøêè ñëóøàþò ðàäèî è ïîêóïàþò è ïîäðóæêàì ñîâåòóþò.
|